Read the full stored bill text
Senate
File
2154
-
Introduced
SENATE
FILE
2154
BY
CAMPBELL
A
BILL
FOR
An
Act
relating
to
the
distribution
of
gene-based
vaccines
and
1
providing
penalties.
2
BE
IT
ENACTED
BY
THE
GENERAL
ASSEMBLY
OF
THE
STATE
OF
IOWA:
3
TLSB
5323XS
(6)
91
ak/ko
S.F.
2154
Section
1.
NEW
SECTION
.
139A.27
Distribution
of
gene-based
1
vaccines
——
restrictions
and
penalties.
2
1.
For
purposes
of
this
section,
unless
the
context
3
otherwise
requires:
4
a.
“Deoxyribonucleic
acid
contamination”
means
an
unintended
5
residual
deoxyribonucleic
acid
fragment
remains
in
a
6
manufactured
gene-based
vaccine.
7
b.
“Distribute”
means
the
delivery
of
a
vaccine
to
an
8
individual
patient.
9
c.
“Gene-based
vaccine”
means
a
vaccine
developed
using
10
messenger
ribonucleic
acid
technology,
modified
messenger
11
riboucleic
acid
technology,
self-amplifying
messenger
12
ribonucleic
acid
technology,
or
deoxyribonucleic
acid
13
technology.
14
d.
“Shedding”
means
the
process
by
which
weakened
components
15
of
a
vaccine
are
released
from
a
vaccinated
individual
into
the
16
environment.
17
e.
“Transmission”
means
the
process
by
which
components
of
18
a
vaccine
are
spread
from
an
individual
who
has
been
vaccinated
19
to
an
unvaccinated
individual.
20
2.
A
manufacturer
shall
conduct
integrative
21
transmissibility,
deoxyribonucleic
acid
contamination,
22
and
shedding
studies
prior
to
the
distribution
of
a
gene-based
23
vaccine
within
the
state.
24
3.
A
person
that
distributes
within
the
state
a
gene-based
25
vaccine
that
poses
an
unreasonable
risk
of
harm
to
public
26
health
through
transmission
or
shedding
as
determined
by
the
27
United
States
food
and
drug
administration
may
be
subject
to
28
a
fine
of
one
thousand
dollars
per
occurrence,
and
licensee
29
discipline
pursuant
to
section
148.6,
if
applicable.
30
4.
A
manufacturer
that
distributes,
sells,
or
uses
a
31
gene-based
vaccine
within
the
state
shall
not
be
immune
from
32
liability
arising
from
injury
or
death
caused
by
a
design
33
defect
in
the
gene-based
vaccine.
34
5.
The
department
of
inspections,
appeals,
and
licensing
35
-1-
LSB
5323XS
(6)
91
ak/ko
1/
2
S.F.
2154
shall
promulgate
rules
pursuant
to
chapter
17A
to
enforce
and
1
administer
this
section.
2
EXPLANATION
3
The
inclusion
of
this
explanation
does
not
constitute
agreement
with
4
the
explanation’s
substance
by
the
members
of
the
general
assembly.
5
This
bill
relates
to
the
distribution
of
gene-based
6
vaccines.
The
bill
defines
“deoxyribonucleic
acid
7
contamination”,
“distribute”,
“gene-based
vaccine”,
“shedding”,
8
and
“transmission”.
9
The
bill
requires
a
manufacturer
of
gene-based
vaccines
to
10
conduct
integrative
transmissibility,
deoxyribonucleic
acid
11
contamination,
and
shedding
studies
prior
to
the
distribution
12
of
a
gene-based
vaccine
within
the
state.
13
The
bill
provides
that
any
person
that
distributes
a
14
gene-based
vaccine
within
the
state
posing
an
unreasonable
15
risk
of
harm
to
public
health,
as
determined
by
the
United
16
States
food
and
drug
administration,
due
to
transmission
17
or
shedding
is
subject
to
a
$1,000
fine
per
occurrence
and
18
licensing
discipline
by
the
appropriate
licensing
authority,
19
if
applicable.
20
The
bill
provides
that
a
manufacturer
that
distributes,
21
sells,
or
uses
a
gene-based
vaccine
within
the
state
is
not
22
immune
from
liability
for
injury
or
death
caused
by
a
design
23
defect
in
the
gene-based
vaccine.
24
The
bill
directs
to
the
department
of
inspections,
appeals,
25
and
licensing
to
adopt
rules
to
enforce
and
administer
the
26
bill.
27
-2-
LSB
5323XS
(6)
91
ak/ko
2/
2